CALIWAY BIOPHARMACEUTICALS CO L

Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries develop drugs for aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is in Phase 2 clinical trials for non-surgical fat reduction, Dercum's disease, and cellulite treatment. The company is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, and it offers dietary supplements. Incorporated in 2012, Caliway is based in New Taipei City, Taiwan.